<DOC>
	<DOCNO>NCT01690286</DOCNO>
	<brief_summary>The purpose study evaluate effect repeat twice-daily administration 200 mg ketoconazole steady-state pharmacokinetics JNJ-38518168 .</brief_summary>
	<brief_title>Effect Ketoconazole Pharmacokinetics JNJ-38518168 Healthy Volunteers</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-sequence , randomize ( dose JNJ-38518168 ( 3 mg 30 mg ) assign chance ) , single-center , multiple-dose study design ass potential effect multiple oral administration ketoconazole ( KTZ ) steady-state ( situation overall intake drug equilibrium elimination ) pharmacokinetics JNJ-38518168 . Pharmacokinetics ( PK ) explore drug absorb body , distribute within body , remove body time . The study consist 3 phase : Screening Phase approximately 3 week ( Days -22 -2 ) ; Open-Label Phase ( Days -1 26 ) ; Follow-up Phase occur 7 10 day last dose study drug . Participants randomly assign receive either daily dose 3 mg JNJ-38518168 ( Group 1 ) daily dose 30 mg JNJ-38518168 ( Group 2 ) orally administer 25 day . All participant receive multiple oral dos KTZ ( 200 mg every 12 hour Groups 1 2 ) Day 22 Day 25 . An optional group participant receive 10 mg daily JNJ-38518168 ( Group 3 ) may evaluate data Groups 1 2 allow sponsor estimate sufficiently interaction KTZ daily dose 10 mg JNJ-38518168 . The participant receive oral dose study drug morning specify day , overnight fast least 10 hour . Blood sample collect various time throughout study evaluation drug concentration plasma . Safety assess report adverse event , vital sign , physical examination result , weight , electrocardiogram ( ECG ) evaluation . Participants leave study center Day 26 collection last scheduled PK blood sample . For participant , follow-up visit occur 7 10 day last dose study drug . For participant , total duration study approximately 8 week .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Signed informed consent document indicate participant understands purpose procedure require study willing participate study If woman , must postmenopausal , surgically sterile , abstinent , , sexually active , practice effective method birth control , throughout , 3 month study If man , must agree use adequate contraception method , partner use effective contraception , donate sperm study 3 month study Body mass index ( BMI ; weight [ kg ] /height2 [ ] 2 ) 18 30 kg/m2 ( inclusive ) , body weight less 50 kg Blood pressure 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic Nonsmoker History current clinically significant medical illness , condition disease investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal lab result screen admission study center Clinically significant abnormal physical examination electrocardiogram ( ECG ) screen admission study center Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen oral contraceptive hormonal replacement therapy within 14 day first dose study drug schedule Has history malignancy ( tendency medical condition , especially tumor , become progressively bad ) within previous 5 year screen ( certain less serious malignancy previous 5 year , basal cell carcinoma skin adequately treat , may allow study doctor ) Donated blood substantial loss blood within 3 month first administration study drug Pregnant currently breastfeed Smoking use nicotinecontaining product within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>JNJ-38518168</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>